The European Commission granted marketing authorization for INVEGA , an atypical antipsychotic medication for the treatment of schizophrenia. This once-daily medication is specifically designed to deliver paliperidone - the active ingredient in INVEGA - through the innovative osmotic delivery system .
From: biz.yahoo.com
TM) Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
Posted by Ruslan Abuzant at 8:02 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment